Eastern Michigan University

DigitalCommons@EMU
Master's Theses and Doctoral Dissertations

Master's Theses, and Doctoral Dissertations, and
Graduate Capstone Projects

2019

Unravelling the D1R-D2R heteromer
Margaret M. Champion

Follow this and additional works at: https://commons.emich.edu/theses
Part of the Biochemistry Commons
Recommended Citation
Champion, Margaret M., "Unravelling the D1R-D2R heteromer" (2019). Master's Theses and Doctoral Dissertations. 988.
https://commons.emich.edu/theses/988

This Open Access Thesis is brought to you for free and open access by the Master's Theses, and Doctoral Dissertations, and Graduate Capstone Projects
at DigitalCommons@EMU. It has been accepted for inclusion in Master's Theses and Doctoral Dissertations by an authorized administrator of
DigitalCommons@EMU. For more information, please contact lib-ir@emich.edu.

Unravelling the D1R-D2R Heteromer
by
Margaret M. Champion
Thesis
Submitted to the Department of Chemistry
Eastern Michigan University
in partial fulfillment of the requirements for the degree of

MASTER OF SCIENCE
in
Chemistry

Thesis Committee:
Hedeel Evans, PhD, Chair
Deborah Heyl-Clegg, PhD, Co-advisor
Jeffery Guthrie, PhD, Co-Advisor

July 9th 2019
Ypsilanti, Michigan

Acknowledgements
I wish to thank my thesis chair, Dr. Hedeel Evans, for her mentorship and support as this
project progressed from an undergraduate side project to a full work. Her assistance in
interpreting experimental results, analyzing data, and preparing manuscripts has been
instrumental to the success of the present work. I am equally indebted to my thesis co-chair, Dr.
Deborah Heyl-Clegg, for sharing her expertise in peptide synthesis. She has also spent hours
editing manuscripts and funding proposals that were essential to the continued success of the
present work, and for this I owe her a debt of gratitude.
I also wish to thank Dr. Jeff Guthrie for his feedback on the present manuscript and his
aid during the experimental stages of the project. I also wish to thank the undergraduates who
worked on this project, particularly Adam Baraka and Pouya Khazaei. Both were incredibly
diligent students who provided hands-on help with the project. Dr. Ruth Ann Armitage provided
mass spectral analysis of all peptides used in this work, and for this I thank her.

ii

Abstract
Dopamine receptors D1R and D2R form a heterooligomeric complex with signaling properties
distinct from the individual receptors. Aberrant expression of this protein-protein complex is
linked to the etiology of various neuropsychiatric diseases. Formation of the D1R-D2R
heteromer is thought to be dependent upon electrostatic interactions occurring between the
carboxyl tail of D1R and the third intracellular loop of D2R. Using this interaction site as
template, I synthesized several peptides designed to disrupt the minimal area of the D1R-D2R
interaction interface and tested these using whole cell lysates of human brain tissue and
dopamine receptor constructs. I report that a synthetic peptide with the sequence EAARRAQE is
efficient in blocking D1R-D2R interaction, while shorter and more highly charged peptides
(EERRAQ, ARRA and AARRAQ) had no effect. This research provides insight into the binding
regions involved in D1-D2 heteromer formation, and may aid future drug development efforts
that target this receptor complex.
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Introduction
Background and Significance
With over 800 characterized members, the G protein receptor (GPCR) protein
superfamily comprises the largest protein superfamily in the mammalian genome.1 GPCR
modulated signal transduction plays a role in physiological processes ranging from head to toe:
from olfaction2 to nail bed growth.3 GPCR dysregulation is implicated in an equally diverse
range of diseases. Diseases whose etiology is linked to perturbations in GPCR signaling include
heart disease, diabetes, Parkinson’s, and Alzheimer’s disease.4-7 Underscoring the importance of
this receptor class, roughly one-third of current drugs target GPCRs.8-9
While they exhibit considerable diversity in structure and ligand recognition, all GPCRs
share essential structural characteristics. All are integral membrane bound proteins with an
extracellular N-terminus and seven intra-membrane α-helices threaded together by a polypeptide
loop that passes three times through the extracellular space and three times through the
intracellular space until ending at the intracellular C-terminus.10 A heterotrimeric G protein
transiently associates with the intracellular loops and C-terminus of the GPCR. It is this
heterotrimeric G protein that will allow signal transduction following receptor occupation. This
G protein consists of three subunits: an alpha subunit and a dimer of the gamma and beta
subunits. This dimer consists of seven antiparallel β sheets (the beta subunit) and an intrinsically
unstable gamma subunit. The alpha subunit is a guanine nucleotide (GTP) binding protein
loosely associated with the beta sheets of the βγ dimer.11 Upon receptor stimulation, the alpha
subunit exchanges bound GDP for GTP, rendering the α-subunit-βγ dimer association
energetically unfavorable and freeing the α-subunit. The freed α-subunit then exchanges GTP for

GDP in downstream events, triggering various signal transduction pathways before returning to
its inactive, GDP binding state, where it associates with another βγ dimer and is ready for the
cycle to begin anew. While binding of the alpha subunit to downstream effectors canonically
mediates signal transduction, it also is worthwhile to note that the βγ dimer also serves as an
independent effector of downstream signaling events, further adding to the diverse effects of
GPCR agonization.12
The diversity of GPCR signaling is further underscored by the fact that GPCRs undergo
ample modification from their initial translation, during which they undergo extensive alternative
splicing,13 and ending with a range of post-translational modifications such as phosphorylation,
glycosylation, SUMOylation, and glycosylation.14 GPCRs can interact with other receptors
through the formation of receptor-receptor complexes (hetero or homomers). These heteromers
have signaling properties that differ from their component receptors and can further modulate
receptor mediated signaling. Notable GPCR heteromers include the adenosine A2A and
glutamate mGlu5 receptor heteromer, the serotonin 5-HT2A and glutamate mGlu2 receptor, and
the adenosine A2A–cannabinoid CB1–dopamine D2 receptor multimer.15
The GPCR landscape is complex and rich, with many unanswered questions and many
potential targets for drug discovery efforts. Our research focuses on the family of GPCRs that
recognize dopamine, a key neurotransmitter. There are five distinct classes of dopamine (D)
receptors, classified as D1-D5. These are further divided into the subclasses of D1-like and D2like based on the activity of the alpha subunit.16 In the broad picture of neuronal signaling, D1like receptors (D1 and D5) are coupled to alpha subunits (GS and Golf) which activate the
regulatory enzyme adenylyl cyclase upon ligand binding to the parent receptor, leading to
activation of the second messenger cyclic amp (cAMP) and triggering signal transduction.17
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Conversely, D2-like receptors (D2R-D4R) are coupled to alpha subunits (Gi and Go) which
inhibit adenylyl cyclase activation and cAMP production.18 Modulation of cAMP modulates the
activity of protein kinase A (PKA), a key regulator of the phosphoprotein DARPP-32. DARPP32 is something of a master switch protein that is acted upon by multiple signal transduction
cascade and whose phosphorylated or unphosphorylated state in turn modulates the activity of
the kinases PP-1 and PKA, as well as calcineurin activated pathways, ultimately regulating the
transcriptional and electrochemical responses to receptor agonization.19 As with other GPCRs,
the βγ subunit is not merely a passive bystander. For dopaminergic receptors generally, the βγ
subunit appears to modulate dopaminergic neurotransmission by regulating activity of the
dopamine transporter, an integral membrane protein responsible for maintaining dopamine levels
in the synaptic cleft.20
Dopamine signaling is further modulated by the ability of the various dopamine
receptors to form heterooligomeric complexes with other receptor types. A heteromeric complex
exists between D2R and the growth hormone secretagogue receptor (GHSR) and fine-tunes the
response to dopaminergic stimulation in neurons (primarily hypothalamic neurons) which coexpress the two receptors.21 The adenosine A1 receptor (A1R) forms a heteromer with D1R, and
signaling through this heteromer seems to play a role in regulating D1R sensitization and in
trafficking of the two receptors.22 Similarly, although adenosine A2 receptors (A2R) are coupled
to stimulatory alpha subunits and D2R to inhibitory alpha subunits, signaling through a
heteromeric A2R-D2R complex modulates D2R signaling by inhibiting D2R internalization.23
D1R and D2R are also known to form a heteromeric complex, and understanding the
coupling of this D1R-D2R is the focus of this thesis. To our knowledge, the first demonstration
of functional linkage between D1R and D2R comes from Lee et al.24 who demonstrated the
3

existence of D1R-D2 heteromeric complexes in the striatum of rat brains and linked signaling
through these complexes to a Gq mediated signal transduction cascade. Subsequent investigations
verified the existence of D1R-D2R heteromers in the human brain25-26 and have allowed the
unique signaling properties of this complex to be understood in some detail.
A simple outline of this pathway is as follows: In response to co-stimulation of D1R and
D2R by dopamine, D1R and D2R form a heteromeric complex.27 Distinct from its constituent
receptors, this D1R-D2R heteromer is uniquely coupled to Gq, which dissociates upon signaling
through the co-stimulation of D1R-D2R.25-26 Activated Gq leads to the activation of
phospholipase C (PLC) and the subsequent hydrolysis of phosphatidylinositol (PI) into inositol
triphosphate (IP3) and diacylglycerol (DAG). The production of IP3 is then associated with the
release of calcium from intracellular stores and the autophosphorylation of calcium/calmodulin
(CaM)-dependent kinase IIα (CaMKIIα). Phosphorylated CaMKIIα then translocates to the
nucleus where it acts as a transcription factor. 26, 28
D1R-D2R heteromer mediated signaling thus represents a unique addition to the
canonical understanding of dopamine signaling. It also provides a point of interplay between
dopamine signaling and multiple other signaling pathways. The original studies of D1R-D2R
heteromeric signaling revealed that calcium release caused by D1R-D2R heteromer agonization
led to upregulation of brain derived neurotrophic growth factor (BDNF).28 BDNF is a necessary
protein for neuron differentiation and growth, and plays a regulatory role in GABAnergic and
glutaminergic signaling.29 Perreault et al.30 have found evidence that the D1R-D2R heteromer
may regulate GABAnergic and glutaminergic signaling in striatal subpopulations of medium
spiny neurons. Together, this suggests that D1R-D2R heteromer mediated signaling has an
important and yet poorly explored impact on neurotransmission.
4

Dysfunction of D1R-D2R heteromeric signaling may also help to explain the etiology of
some complex diseases canonically linked to dopaminergic signaling. Perreault et al.31 have
provided evidence that the D1R-D2R heteromer is enriched in the paleostriatum of individuals
with schizophrenia, and that D2 receptors in these heteromeric complexes showed higher affinity
for the synthetic dopamine receptor agonist SKF 83959 than D2 receptors in the brains of normal
individuals did. Further evidence for a link between D1R-D2R signaling and schizophrenia is
seen in mechanistic studies of the antipsychotic clozapine, which exerts its effects through
disrupting the D1R-D2R heteromer.32 Nor is schizophrenia the only disorder of dopamine
signaling linked to aberrant D1R-D2R heteromer expression: Studies of Parkinson’s disease in
animal models revealed that the D1R-D2R heteromer is enriched in striatopallidal neurons of
animals with induced Parkinsonian symptoms compared to normal controls.33 Conversely,
signaling through the D1R-D2R heteromer seems to blunt the D1R mediated signaling pathway
triggered by cocaine and ameliorates cocaine dependency in rats.34 Finally, the population of
striatal dopamine receptors is found to be shifted towards the D1R-D2R heteromeric state in
patients with major depression.35
Together, this suggests that signaling through the D1R-D2R heteromer not only mediates
neurotransmission in a novel way, but also implicates this complex in the etiology of diseases
affecting dopaminergic signaling. One tool for investigating this complex has been the
development of synthetic peptides that inhibit or abolish D1R-D2R coupling by mimicking the
binding interface between the complex.34,35
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Contribution of the Current Research
Early research by Łukasiewicz et al.36 narrowed down the interaction interface between
D1R and D2R to a region of the third intracellular loop of D2R containing a pair of adjacent
arginines (217RRRRKR222) and a region in the carboxyl tail of D1R containing two adjacent
glutamic acids (404EE405). This region was further determined by O’Dowd et al.37 to be a six
amino acid stretch (271–EAARRA). A pair of adjacent arginine residues (274-RR) in this
sequence forms a salt bridge with two adjacent glutamic acids in the D1 receptor carboxyl tail,
which is essential to heteromer formation.
The present work used this model of the D1R-D2R interaction interface to design a
peptide with a minimal sequence but with the capacity to abolish coupling between the two
parent receptors. Four peptides with potential to disrupt D1R-D2R coupling were synthesized
four peptides aimed at disrupting D1R-D2R heteromerization and tested on both in vitro
translated D1R and D2R proteins and in whole cell lysates of brain. Of the four sequences tested,
one was successful in disrupting the D1R-D2R heteromer. This peptide, bearing the sequence
EAARRAQE, is based off the shortest sequence of amino acids in the third intracellular loop of
the D2 receptor that O’Dowd et al.37 implicate in heteromer formation. A mutant peptide with
sequence EERRAQ showed some effect but was notably less effective than the longer native
sequence EAARRAQE in disrupting heteromer formation. Two shorter peptides (ARRA and
AARRAQ) were synthesized with the aim of disrupting the minimal possible interaction site of
the four amino acids that form salt bridges between D1R and D2R. These showed little to no
effect.
Finally, this work explores the role of a D-isoform of the most successful peptide,
EAARRAQE, in disrupting the D1R-D2R heteromer. D-peptides have unique stereochemical
6

properties that make them potentially more efficacious therapeutic agents than their Lcounterparts, and as such are being increasingly explored as potential therapeutic agents.38 Our
results were inconclusive but promising for future study.
By establishing a minimal peptide sequence that abolishes D1R-D2R coupling, this work
sheds light upon the structural basis of D1R-D2R interaction. This research aids further
investigation of this complex, both in elucidating its structure and in the development of drugs
that target the complex. More broadly, this research contributes to the overall development of
drugs that inhibit interaction between other GPCR heteromers.
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Materials and Methods
Purchase and Isolation of Dopamine Receptor DNA
HaloTagged pFN21A plasmid vectors containing full length human D1R and D2R and
ampicillin resistance marker were purchased from Promega. Plasmid transformation into DH5α
competent cells was performed using standard protocols. Colonies were picked from a selection
plate the following day, expanded, and plasmid purification performed using a Wizard® Plus SV
Minipreps Start-Up Kit purchased from Promega.
Expression via Transcription/Translation Kit
D1R and D2R proteins were generated via expression in a TnT® Quick Coupled
Transcription/Translation System purchased from Promega, following manufacturer instructions.
Briefly, 100 ng of plasmid DNA containing a T7 promoter and encoding the entire dopamine
receptor was added to a microfuge tube containing 40 µL TnT® Quick Master Mix, 1 µL of 1
mM methionine, and nuclease free water to a total volume of 50 µL. Tubes were incubated for
80 minutes at 30°C. Correct protein expression was verified via SDS Page. Protein concentration
was determined using a Pierce™ BCA Protein Assay Kit purchased from Thermo Scientific.™
Solid Phase Peptide Synthesis
Solid phase peptide synthesis was carried out using a Protein Technologies PS3
synthesizer. Four-fold excess of amino acids was weighed, with reactive amino groups protected
by a fluorenylmethyloxycarbonyl (Fmoc) protecting group. For both L- and D- amino acids, the
glutamic acid side chains were protected using a tert-butyl ester group, glutamine protected using
a trityl group, and arginine protected with a 2,2,5,7,8-pentamethyl-chroman-6-sulphonyl (Pmc)
group. All amino acids were purchased from Anaspec, Inc. Peptides were acetylated at the Nterminal and amidated at the C-terminus. These modifications eliminate positive N-terminal
8

charges and negative C-terminal charges, resulting in a peptide that more closely resembles
segment of the native polypeptide chain.
The C-terminal amino acid was attached to a Rink amide linker attached to a MBHA
resin support on a 0.1 mmol scale. Rink amide resin was purchased from Nova Biochem. The
chemical 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (HBTU)
was used as a coupling agent to induce amide bond formation between amino acids and a
solution of 20% piperidine in dimethylformamide (DMF) was used then to deprotect reactive
amino groups for the next coupling. The coupling agent HBTU was purchased from Anaspec,
Inc. After synthesis, peptides were acetylated with acetic anhydride and then cleaved from the
resin by scraping the resin into a beaker containing 10 mL of a solution containing 5% phenol
scavenger, 2% triisopropylsilane (TIS), and 5% distilled water in trifluoroacetic acid (TFA). This
solution was stirred for two hours at room temperature. Peptides were then precipitated from the
solution using diethyl ether chilled to 4°C, filtered with a fritted filter funnel and dissolved in a
solution of 35% acetonitrile in water, and lyophilized overnight under vacuum. After
lyophilization, peptides were dissolved in neat TFA and purified using reversed-phase high
performance liquid chromatography. The stationary phase consisted of a Phenomenex C18
column (25 cm x 2.2 cm), with the aqueous component of the liquid phase composed of 0.1%
TFA in water and the organic component of the liquid phase composed of 0.1% TFA in
acetonitrile. The gradient ran between 10% to 50% organic phase over a period of two hours,
with the majority of the sample eluting within 40 minutes of run start. The solvents acetonitrile
and dimethylformamide were purchased from EMD Chemicals, Inc., while piperidine,
triisopropylsilane, ether, phenol, acetic anhydride, and trifluoroacetic acid were purchased from
Sigma-Aldrich. Tubes containing desired peptide were then lyophilized.
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Analytical HPLC to verify purity was performed using a Phenomenex C18 column (25
cm x 4.6 mm). Peptides were then analyzed with paper spray ionization mass spectrometry to
confirm molecular weight.
Coimmunoprecipitation and Dot Blotting

A 1000 µM stock solution of peptide was created by weighing the appropriate mass of
peptide and dissolving it in a solution of 10% DMSO in phosphate buffered saline (PBS).
Powdered phosphate buffered saline was purchased from Sigma-Aldrich. This stock was added
to a series of microfuge tubes containing 3 µg of D1R and 3 µG D2R receptor proteins translated
using a TnT® Quick Coupled Transcription/Translation System as described above. Phosphate
buffered saline at pH 7.0 was used to adjust the volume of each tube to 50 µL, and then 20 µL of
pre-washed Protein A/G PLUS-agarose beads purchased from Santa Cruz Biotechnology
conjugated to D1R were added to each tube. This solution was incubated overnight at 4 °C on an
orbital shaker.
The following day, the samples were precipitated by centrifugation at 3000 xg for 1
minute, and then cleared by washing three times in 400 µL Tris-Buffered Saline and Tween 20
(TBST). Bound protein was released from the beads by boiling for 10 minutes in a 100 oC water
bath. Following release of bound protein, 10 µL of resultant sample was spotted onto a
nitrocellulose membrane. Nitrocellulose membranes were purchased from Sigma-Aldrich. This
membrane was allowed to dry for 10 minutes at room temperature before being blocked
overnight in 5% milk in TBST. Following blocking, membranes were washed three times for
five minutes each in TBST, then incubated overnight in 2.5% milk in TBST containing a 1:1000
dilution of primary antibody for D2R, washed in TBST and then incubated overnight again in
2.5% milk in TBST containing a 1:10,000 dilution of secondary antibody for D2R. Blots were
developed using SuperSignal™ West Pico PLUS Chemiluminescent Substrate from
10

ThermoFisher and imaged on a Bio-Rad molecular imager. Quantitation was performed using
ImageJ 1.47v software downloaded from the National Institutes of Health and graphed using
GraphPad Prism 8.0.
Whole Cell Lysate Testing
Total protein lysate isolated from adult normal frontal and temporal lobe (catalog numbers
P1234051 and P1234078, respectively) and depressed temporal frontal and temporal lobe (catalog
numbers P1236051Dep and P1236078Dep, respectively) were purchased from BioChain. Institutional
Review Board approval was not necessary for the procurement of these protein lysates.
Western Blotting

We incubated 50 µg total of whole tissue lysate overnight in a total volume of 50 µL
TBST either alone (control) or containing peptide. After incubating 24 hours, 20 uL of A/G
PLUS-Agarose beads conjugated to D1R were added to each tube to capture the complex. These
were incubated for 24 hours at 4 °C with shaking. Sample tubes were then centrifuged at 4000
rpm for 1 minute at 4 °C, the supernatant removed, and the beads washed with 800 µL of cold
PBS. This process was repeated four times and 10 uL of 5X SSB was added to release the
protein complex from the beads. The protein complex was released from the agarose beads by
incubation for ten minutes in an 80 °C water bath. Ten microliters of protein were run on a 12%
acrylamide gel for 2.5 hours at 100 V and then transferred to western blot and run for one hour.
The resulting membrane was blocked overnight in 5% milk in TBST. Following overnight
incubation, the membrane was washed three times for five minutes in TBST and then incubated
in a solution of 2.5 % milk in TBST containing a 1:10000 dilution of rabbit polyclonal anti-D2R
antibody. After an incubation period of 12 hours, the membrane was again washed three times in
TBST for five minutes per wash and incubated for 12 hours in a solution of 2.5% milk in TBST
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containing a 1:20,000 dilution of goat anti-rabbit IgG HRP tagged secondary antibody. Both
antibodies were purchased from Abcam.
Following a 12-hour incubation, the membrane was washed five times in TBST,
developed with Pierce™ ECL Western Blotting Substrate and imaged on a BioRad Molecular
Imager. Following imaging, the blots were quantitated with ImageJ software and analyzed using
Graphpad Prism 8.0.
ELISA
For D1R-D2R binding assays, 60 ng of D2R protein in 100 µL PBS was bound to the
wells of Nunc MaxiSorp™ multiwell plates purchased from ThermoFisher. Coated plates were
incubated for 24 hours at 4 °C. Subsequently, plates were washed three times with 200 µL TBST
and blocked in IB-BSA buffer (1 M Tris-Cl, 1 M MgCl2, 5 M NaCl, 100 μL Tween 20, 1 g
bovine serum albumin). After 24 hours, plates were washed as described above and increasing
concentrations of D1R protein in PBS were added to each well. The proteins were incubated
together for 48 hours, washed three times with TBST (200 µL added to each well, then plates
rotated for five minutes on an orbital shaker), and incubated overnight in 50 µL PBS containing a
1:500 dilution of mouse monoclonal primary antibody for D1R. After 12 hours the plate was
washed three times with TBST as described above and then incubated for 12 hours in 50 µL PBS
containing a 1:10000 dilution of HRP-conjugated anti-mouse (mouse IgGκ binding) secondary
antibody. Both antibodies were purchased from Santa Cruz Biotechnology. Plates were then
washed three times in TBST, and binding activity assayed via colorimetric reaction with 100 µL
room temperature TMB (3,3´,5,5´-tetramentylbenzidine) purchased from Thermo Fisher. After
10 minutes the reaction was quenched by adding 100 μL of 2 M H2SO4 and absorbance at 450
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nm was measured using a Biotek plate reader. ELISA data was graphed and analyzed using
GraphPad Prism 8.0 software.
For peptide interference assays, 1000 µg of L-EAARRAQE was dissolved in 1 mL of a
solution containing 10% DMSO in PBS. This stock solution was diluted in PBS to create a final
concentration of 60 nM and used to coat the wells of a 96 well Nunc MaxiSorp™ ELISA plate.
After a 24-to-48-hour incubation period, the plate was rinsed three times with TBST, and a serial
dilution of either D1R or D2R was added to the wells such that concentrations ranged from 1000
nM to 1 nM. After overnight incubation at 4 °C on an orbital shaker, plates were washed three
times by adding 200 µL of TBST and then probed using anti-D1R or anti-D2R antibodies. Plates
were developed and imaged as per previous protocol.
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Results and Discussion

Expression of D1R and D2R Proteins in Vitro

Due to the inherent difficulties of expressing and purifying transmembrane proteins, the
choice was made to express D1 and D2 receptors in a cell-free system. This procedure is
discussed fully in the Materials and Methods. Figure 1 shows that both dopamine receptors were
successfully expressed using this system.

1

2

3

4

 35 kDA

Figure 1. Verification of Properly Expressed Receptors. 3 μg of plasmid DNA encoding D1R (lanes 1 and 2) and
D2R (lanes 3 and 4) was expressed using a TnT® Quick Coupled Transcription/Translation Systems kit.

Clean, sharp bands can be observed around 35 kDA for D1R and 38 kDA for D2R. These
are slightly lower than the reported sizes of 48 kDA for D1R and 50 kDA for D2R commonly
observed in in vivo studies of these receptors, a discrepancy likely due to the lack of posttranslational modifications for in vitro translated receptors. Similar results are seen in Fishburn et
al.39
The next step was to demonstrate that in vitro expressed D1R and D2R form heteromeric
complexes. Additionally, extensive literature review revealed little data on the binding affinity
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between D1R and D2R (a measure of how easily the interaction between the two happens). To
generate this data, we used enzyme-linked immunosorbent assays (ELISA) to demonstrate the
ability of our in vitro expressed receptors to bind to each other, as well as to determine the
affinity of interaction between D1R-D2R. Briefly, a fixed concentration of D2R was bound to
the wells of an adsorbent plate, then incubated in the presence of varying concentrations of D1R.
Extensive washing removed any unbound protein from the plate, allowing the extent to which
the two proteins bind to be quantitated. All ELISA assays were run in triplicate under conditions
as described in the Materials and Methods. Results of ELISA assays are seen in Figure 2.

Figure 2. D1R binds to D2R with high affinity. D2R (60 nM) was bound to the wells of a 96 well Nunc Maxisorp Plate.
Following overnight blocking, the plate was then incubated with a serial dilution of D1R. The amount of D1R was
visualized using anti-D1R specific antibodies and developed using TMB. D1R concentration was expressed as a function of
optical density and plotted in GraphPad Prism, with each data point representing the average optical density measurement ±
standard deviation over three runs of each assay.

The KD (a measure of the ease at which the two receptors form a complex) was calculated
using GraphPad Prism 8.0, as described in the Materials and Methods. This value was found to
be 3.0 ± 0.7 nM. While this data does not demonstrate the binding affinity between native D1R15

D2R, it does suggest that in vitro expressed D1R and D2R are capable of forming a complex.
This demonstration validates the use of in vitro translated receptors as a tool for studying the
D1R-D2R complex and provides information about the affinity of interaction between the two.
With translated receptors as a tool in hand, we were able to proceed to testing the effects of
various peptides on disrupting interaction between D1R-D2R.
Peptide Design and Testing
As discussed, experiments by O’Dowd et al.37 suggest that D1R-D2R
heterooligomerization is mediated by electrostatic interactions occurring along a six amino acid
stretch between the third cytoplasmic loop of D2R and the D1R carboxyl tail. This
heterooligomerization is particularly dependent upon salt bridge formation between two adjacent
arginines in the third cytoplasmic loop of the D2 and two glutamic acids in the D1 receptor
carboxyl tail. The proposed interaction site is seen in Figure 3.
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D1 receptor (D1R)

D2 receptor (D2R)

Figure 3. Proposed Interaction Interface between D1R and D2R. Snake plot representation of the D1 and D2
receptors drawn with GPCRdb webserver (http://gpcrdb.org/). This model suggests that binding between D1R and
D2R occurs through the interaction of residues within a 6 amino acid long stretch between the carboxyl tail of the
D1 receptor and the third cytoplasmic loop of the D2 receptor. Interaction between two adjacent arginines in the D2
receptor and two glutamic acid residues in the D1 receptor is necessary for heteromer formation. Reprinted with
permission from ref 40. Copyright 2019 Heyl et al.

Using as template the third intracellular loop of D2R believed to couple to D1R, four
peptides were synthesized. The first peptide, EAARRAQE, was designed to fully correspond to
the shortest sequence of D2R that most completely contacts D1R. The second peptide,
EERRAQ, does not correspond to the native D1R-D2R binding interface but instead is a more
highly charged “mutant” with glutamic acid substituted for the wild-type alanine residues. This
modification was designed to increase electrostatic interactions between the peptide and a pair of
lysine residues in D1R.
Peptide three, ARRA, corresponds to the smallest possible sequence of D2R that
preserves the adjacent arginines believed to be critical to D1R-D2R heteromer formation.
Peptide four, AARRAQ, was designed to preferentially bind to the six amino acid sequence in
17

D1R (KKEEAA, Fig. 3) identified by O’Dowd et al.37 as essential to D1R-D2R heteromer
formation. Peptide sequences and molecular weights are summarized in Table 1.
Table 1. Synthetic peptide sequences and molecular weights. N-terminal acetyl groups were added to prevent
non-native charges. All peptides are carboxamides at the C-terminus.

Sequence

Molecular Weight (Daltons)

Ac-EAARRAQE

971.5

Ac-EERRAQ

829.4

Ac-ARRA

514.3

Ac-AARRAQ

713.4

All peptides were synthesized using a PS3 solid phase peptide synthesizer with Rink
amide MBHA resin and an Fmoc protection scheme, as described in the Materials and Methods.
Coimmunoprecipitation Experiments
The possible efficacy of each peptide sequence in disrupting D1-D2 heteromer formation
was tested via coimmunoprecipitation as described in the Materials and Methods section. It
should be noted that dot blotting for peptides three and four was performed in collaboration with
student colleagues. Figure four shows examples of dot blotting results for each peptide tested.
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Figure 4. Co-Immunoprecipitation of Expressed D1R and D2R in the Presence of Increasing Peptide. Expressed D1
and D2 receptors were incubated overnight in the presence of increasing concentration of peptide. Receptors were
then co-immunoprecipitated with agarose beads conjugated to anti-D1R antibody, then released from the beads by
boiling and spotted onto a nitrocellulose membrane. After overnight blocking in 5% milk in TBST, membranes were
probed with anti D2R primary and secondary antibodies and imaged. Receptor concentration is directly correlated to
density of pixels i.e darkness of the image. From left to right, concentrations are 0, 15, 25, 150, 200, 250, and 300
nM of peptide. All experiments were run in triplicate.

A strong visual trend of decreasing signal intensity with increasing peptide concentration
is observed in the blot for EAARRAQE, the peptide designed to most fully cover the native
D1R-D2R binding interface. The mutant peptide, EERRAQ, displays a more ambiguous trend:
an overall decrease in signal intensity is observed, but in a less dramatic and less linear fashion
than for EAARRAQE. ARRA and AARRAQ show little decrease in signal intensity. As a
quantitative measure of these results, the concentration at which each peptide displayed halfmaximal inhibition was calculated. This value was found to be 72 ±15 nM. Results are seen in
Figure 5.
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72 ±15 nM

Figure 5. EAARRAQE Disrupts D1R-D2R Interaction. Graphical representation of coimmunoprecipitation
experiments. Signal intensity was normalized by plotting ratio of mean signal intensity to maximal binding, then fit to
peptide concentration using a nonlinear regression curve. Data was quantitated in ImageJ and processed in GraphPad
Prism 8.0. The graph summarizes the results expressed as means ± standard deviation and normalized to control (P <
0.05, n = 5).

Based on this data, it seems that EAARRAQE is most efficient at interfering with D1RD2R heteromer formation. While only differing by two amino acid residues, EERRAQ and
AARRAQ show very little effect, suggesting that the full coverage of the D1R-D2R interaction
interface may be necessary to disrupt the interaction between the two receptors. This trend holds
true for both the modified peptide EERRAQ and the native peptide AARRAQ.
However, coverage of the D1R-D2R interaction interface is not sufficient in disrupting
D1R-D2R interaction. While equal in length, the highly charged EERRAQ is noticeably better at
disrupting D1R-D2R interaction than the native AARRAQ is. This may underscore the
importance of electrostatic interactions in forming the D1R-D2R heteromer.
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The inability of peptide three (ARRA) to abolish or even diminish D1R-D2R coupling
suggests that the EE: RR interaction between D1R-D2R is necessary but not sufficient for
heteromer formation. Taken as a whole, the sequence EAARRAQE seemed the most promising
for further testing.
D1R and L-EAARRAQE Interact with High Affinity
We next wished to quantitate the extent to which L-EAARRAQE interferes with D1RD2R coupling. As described in the Materials and Methods, a stock of L-EAARRAQE was used
to coat the wells of a Nunc MaxiSorp™ ELISA plate. Following this step, resuspended D1R and
D2R was added in increasing concentrations. This assay was repeated for a total of three unique
runs, data from which were pooled, normalized, and used to generate a binding curve for D1R
and D2R in the presence of L-EAARRAQE. This binding curve is seen in Figure 6.
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4.6 ± 0.8 nM.

Figure 6. D1R Binds to L-EAARRAQE and D2R with Comparable Affinity. Results of D1R and D2R incubated in 96 well
ELISA plate pre-treated with L- EAARRAQE. Levels of D1R or D2R were measured via HRP conjugated antibodies. Each
data point represents the pooled mean ± standard deviation of three separately run ELISA assays. K0 was calculated using
GraphPad Prism 8.0 and found to be 4.6 ± 0.8 nM.

While D2R and L-EAARRAQE do not bind to each other, D1R and L-EAARRAQE
interact with a binding affinity of 4.6 ± 0.8 nM. Although this value is higher than the 3.0 ± 0.7
nM (Fig. 2) between D1R-D2R, it seems to be sufficient to competitively inhibit interaction
between the two receptors. This implies that the sequence L-EAARRAQE fully comprises the
necessary binding region for native D1R-D2R heteromer formation. These results demonstrate
the ability of L-EAARRAQE to effectively inhibit D1R-D2R coupling in vitro. However, as
previously noted, both D1R and D2R undergo extensive post-translational modification.13-14, 39
As such modifications would be absent in our in vitro model, a full demonstration of the efficacy
of L-EAARRAQE in inhibiting D1R-D2R interaction must be made in a model of this system
that accounts for such changes. While studying this complex in situ was not a feasible option,
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whole tissue lysates of human cerebral tissue offered a viable and directly physiologically
relevant model.
Total Protein Lysate Testing
Having had success in in vitro models, we were interested in whether D1R-D2R
heteromers could be detected and disrupted in in tissue lysates. Pei et al. originally demonstrated
both that the D1R-D2R heteromer is upregulated in striatal tissue isolated from depressed
patients. In the same study, the authors demonstrated that administration of peptide designed to
disrupt the D1R-D2R heteromer resulted in modulation of behavioral symptoms of depression in
rats if administered to the prefrontal cortex, but not if administered to the hippocampus or
nucleus accumbens.35 This tissue specificity was intriguing to us, as the presence of D1R-D2R
heteromers is well established in the striatum,41 but region specific differences in heteromer
density are otherwise poorly characterized.
For these reasons, we attempted to analyze two regions where D1R-D2R heteromer
density is, to our knowledge, not fully explored. The success of Pei et al.35 in creating a D1RD2R disrupting peptide capable of alleviating behavioral symptoms of depression inspired us to
seek direct evidence that our own D1R-D2R disrupting peptide might have differential effects in
vivo. Results of this testing reproduced from Heyl et al.40 are seen in Figure 7.
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Figure 7. L-EAARRAQE Disrupts D1R-D2R Interaction in Total Protein Lysate. Quantitative summary of D2RD1R coimmunoprecipitation and western blotting. In vitro expressed receptors (PR), normal frontal lobe (NF),
depressed frontal lobe (DF), normal temporal (NT), and depressed temporal (DT) were incubated overnight either
in TBST (left) or in a solution of 10 nM of L-EAARRAQE in TBST. Bar graphs represent mean value ± standard
deviation of D1R signal intensity in sample treated with L-EAARRAQE relative to D1R signal intensity in
untreated controls. Reprinted with permission from ref 40. Copyright 2019 Heyl et al.

These results demonstrate that the D1R-D2R heteromer can be detected in total protein
lysate derived from frontal and temporal lobes, suggesting that this protein-protein interaction is
not limited to the areas previously discovered. Additionally, they suggest that EAARRAQE
effectively prevents D1R-D2R heteromer formation in total protein lysate. Interestingly, it seems
to do so equally well in samples obtained from non-depressed subjects as it does in samples
obtained from depressed subjects.
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D-Isoforms of EAARRAQE
All proteins are built from the stringing together and folding of chains of amino acids,
and almost all physiologically relevant amino acids have the same rotational configuration
around a single chiral carbon atom. However, 19 out of 20 of the physiological amino acids
(excepting glycine, which does not have a chiral carbon) have another form with mirrored
symmetry. Due to this mirrored symmetry, D-amino acid peptides have slightly different
physiological properties that are sometimes exploited in nature. In humans, D-aspartate is a
critical regulator of neonatal brain development and continues to modulate hippocampal
neurogenesis through adulthood.42 Agonization of N-methyl-D-aspartate (NMDA) glutamate
receptors requires stimulation both by glutamate and a coactivating second molecule, which can
be either glycine or D-serine.43 More directly relevant to our research, though, is the use of Damino acids as therapeutic agents. D-amino acids are not targeted by proteases to the same extent
as their L-amino acid counterparts are, making D-amino acids a target of research for the
development of peptide drugs.38 This raised the question of whether the D-isoform of
EAARRAQE would be effective in blocking the D1R-D2R interaction.
To test this, a D-isoform of EAARRAQE was synthesized using the solid phase peptide
synthesis method previously described and tested on total protein lysates concentrations of
peptide, then D1R was used to immunoprecipitate D2R as described in the previous experiment
with in vitro translated receptors, and western blotting performed on the immunoprecipitated
complex as described in the Materials and Methods. However, supplies of total protein lysate
were limited, and thus only two runs of this experiment were possible. Figure 8 shows
representative scans of western blots testing D-EAARRAQE in total protein lysate obtained from
patients with (Fig. 8A) or without (Fig. 8B) a history of depression.
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Figure 8. D-EAARRAQE disrupts D1R-D2R interaction in brain tissue total protein lysate. Sample was left
untreated (left) or treated with 10 nM D-EAARRAQE (right). A. Western blot of total protein lysate (50 µG) from
depressed temporal lobe brain tissue. B. Western blot of total protein lysate (50 µG) from normal temporal lobe
brain tissue. Sample was left untreated (left) or treated with 10 nM D-EAARRAQE (right).

The signal intensity of the untreated control (Fig. 8) is notably stronger for untreated
controls than for samples treated with 10 nM of D-EAARRAQE. As with the experiments using
L-EAARRAQE (Fig. 7) this trend of decreased signal intensity following peptide treatment
holds true both for samples obtained from depressed (A) or neurotypical (B) adults. From these
preliminary experiments, it would appear that D-EAARRAQE is capable of blocking D1R-D2R
interaction in whole tissue lysate samples. Whether it is more efficient at doing so than LEAARRAQE remains to be seen. A quantitative representation of these western blotting
experiments is seen in Figure 9.

.
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Figure 9. Graphical Summary of L- and D-EAARRAQE western blotting experiments. Bar graphs represent mean value ±
standard deviation of D1R signal intensity in sample treated with D-EAARRAQE relative to D1R signal intensity in
untreated controls. Values are obtained from two independent western blotting experiments with D-EAARRAQE in each
condition and two independent western blotting experiments with L-EAARRAQE in each condition.

This data strongly suggests that D-EAARRAQE is capable of interfering with D1R-D2R
interaction. However, it must be noted that each data point represents the average over only two
runs of the represented condition. As such, extensive variability exists between each run and so
far, no conclusions can be drawn from this data as to whether D-EAARRAQE is more
efficacious than its L-counterpart. Unfortunately, as mentioned above, a lack of sample
prevented any further testing.
While not yet conclusive, we believe that these initial results warrant further study. If
these results were eventually borne out by further tests, this differential effect could be explained
by the presence of active peptidases in the total protein lysate sample, to which the D-peptide is
less susceptible. It is also possible that the D-isoform has structural features that make it more
efficacious at binding to D2R. While the L- and D- isoforms of EAARRAQE should exactly
mirror each other, it is possible that the mirrored switch between L- and D- isoforms leads to a
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shift of the peptide’s backbone dipole. This possibility is being explored by Towse et al.42 as a
general feature of D-peptides. If so, D-EAARRAQE may possess slightly different electrostatic
properties than those of L-EAARRAQE. A demonstration that the mirrored symmetry of L- and
D-peptides has relevant effects on disrupting the D1R-D2R heteromer would add greatly to our
knowledge of peptide therapeutics. For these reasons, we believe that these investigations may
be worth pursuing to future researchers, but the present work must conclude with this question
unanswered.
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Conclusion and Future Directions
The traditional view of dopaminergic signaling has been enriched by the discovery of a
novel signaling pathway mediated by a heteromeric complex that forms between dopamine D1
and D2 receptors. Interaction between these two proteins is believed to take place via salt bridge
formation between two arginine residues in the third intracellular loop of the D2 receptor and
two glutamic acid residues in the carboxyl tail of the D1 receptor. Using this interaction interface
as a template, we designed several peptides with the goal of abolishing D1R-D2R coupling. One
of these peptides, bearing the sequence EAARRAQE, was successful at disrupting the D1R-D2R
interaction both in translated receptor proteins and in total protein lysate derived from human
cerebral tissue. This peptide was successful in disrupting D1R-D2R interaction, while a shorter
peptide (ARRA) aimed at disrupting the minimal interaction interface between D1R-D2R was
unsuccessful. EAARRAQE was also more successful than a shorter native sequence (AARRAQ)
and a mutant, highly charged sequence (EERRAWQ). Altogether, this suggests that both full
coverage of the binding interface between the two receptors and charge-charge interactions are
necessary to disrupt D1R-D2R coupling. While other researchers have created peptide sequences
that successfully disrupted D1R-D2R coupling, to our knowledge this is the shortest peptide to
successfully disrupt this protein-protein interaction.
Additionally, we have synthesized a D-isomer of this peptide. As mirror images
of the physiological amino acids, D-amino acids have slightly different interactions with
physiological proteins. Initial studies with D-EAARRAQE are inconclusive due to lack of
sufficient sample to fully test the hypothesis that a D isoform of L-EAARRAQE will have
differential effects. Further experiments are thus advised in order to determine what, if any,
effect exists here. Overall, our findings have relevance to the study of the structural dynamics of
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D1R-D2R heterooligomers and may represent a novel tool for investigating potential therapeutic
manipulations of this complex.
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